Related Experiment Video
Updated: Mar 16, 2026

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Current and Emerging Therapies of Severe Epileptic Encephalopathies
Abeer J Hani1, Mohamad A Mikati2
1Department of Pediatrics and Neurology, Lebanese American University, Byblos, Lebanon.
Insights
New therapies for pediatric epileptic encephalopathies are emerging, targeting specific genetic and autoimmune causes. This review updates on novel treatments and personalized approaches for these severe childhood epilepsy syndromes.
Area of Science:
- Neurology
- Pediatric Epilepsy
- Genetics
Background:
- Pediatric epileptic encephalopathies are severe neurological disorders characterized by frequent seizures and developmental impairment.
- Current treatment paradigms often lack targeted approaches for specific underlying etiologies.
Purpose of the Study:
- To review current and emerging treatment options for pediatric epileptic encephalopathies.
- To highlight the impact of identifying specific genetic and autoimmune causes on therapeutic development.
Main Methods:
- Literature review of recent advancements in the treatment of pediatric epileptic encephalopathies.
- Analysis of novel therapeutic strategies targeting disease pathophysiology.
Main Results:
- Identification of specific genetic and autoimmune causes enables targeted therapy development.
- Emerging treatments offer potential for improved outcomes in pediatric epileptic encephalopathies.
Conclusions:
- Advances in understanding disease mechanisms are driving the development of novel, personalized therapies.
- Targeted treatment strategies hold promise for better management and improved prognosis in pediatric epileptic encephalopathies.
Abstract:
In this article, we review the treatment options for the pediatric epileptic encephalopathies and provide an update on the new and emerging therapies targeted at the underlying pathophysiology of many of these syndromes. We illustrate how the identification of the specific genetic and autoimmune causes has made possible the evaluation and development of novel, better targeted therapies, as and at times, avoidance of potentially offending agents.
More Related Videos
09:07Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
06:55Author Spotlight: Unraveling Neural Communication and Circuit Interactions in Health and Disease
Published on: November 21, 2024
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Electroconvulsive Therapy
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...